On August 13, 2026, an entrepreneur exchange event hosted by the Royal Thai Consulate General in Guangzhou was successfully held in Guangzhou. With the core objective of building a bridge for Sino-Thai collaborative development in advanced medical technologies, the event attracted over 50 key representatives from Thailand's political, business, and academic sectors, as well as several outstanding enterprises in China's biomedical field, creating a high-value exchange platform for cross-border industrial resource alignment and technological cooperation. The Cell Valley Group was specially invited by Mr. Kajtiti Wiwatwanont, Consul General of Thailand in Guangzhou. Deputy General Manager Xiang Hua and Dr. Fu Yuchen, Director of the International Medical Service Center, attended the event, engaging in in-depth discussions with Thai representatives from various sectors, sharing the company's innovative achievements in the cell and gene therapy (CGT) field, and actively promoting the implementation of Sino-Thai medical industry cooperation.

        The Thai delegation at this event covered multiple core sectors including government administration, higher education, healthcare, financial investment, and industrial entities, establishing comprehensive and efficient channels for multi-dimensional Sino-Thai industrial cooperation.

        During the on-site exchange session, Dr. Fu Yuchen highlighted the Cell Valley Group's full-chain industrialization advantages in the CGT sector: the Group has established a mature integrated "R&D – Clinical – Service" system, mastering core immune cell therapy technologies including CAR-T and CAR-NK, and has built a diversified medical product pipeline encompassing NK cells, γδT cells, and mesenchymal stem cells. Addressing the specific demands of the Thai market, the team elaborated on three key directions: localization of technology, full-cycle patient services for cross-border patients, and synergistic development of Sino-Thai medical resources—precisely matching Thailand's core needs for upgrading premium medical services and advancing clinical translation.

        During the event, participants engaged in in-depth discussions on the challenges and viable pathways for cross-border implementation of advanced medical technologies, taking into account the medical policies, clinical resource profiles, and market demands of both countries. Moving forward, the Cell Valley Group will leverage Thailand's well-established medical tourism infrastructure and clinical resource advantages to collaborate with local Thai institutions on clinical research cooperation for cell therapy products, assist Thai cell therapy centers in upgrading their technologies and establishing standardized systems, and provide integrated services including technology translation and talent exchange for partner enterprises in both countries. Together, they aim to lower the barriers and costs of accessing advanced medical technologies, ensuring that innovative outcomes benefit a broader patient population.